Provention Bio Chooses Amber as Specialty Pharmacy for Tzield
Tzield addresses the underlying cause of the disease, where the immune system destroys the insulin producing cells in the pancreas. It is administered by intravenous infusion once daily for 14 consecutive days.
Amber Specialty Pharmacy will be dispensing Provention Bio’s Tzield (teplizumab) to delay the onset of stage 3 type 1 diabetes. It is indicated for adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. Tzield is anti-CD3-directed antibody, and binds to CD3, a cell surface antigen present on T lymphocytes. Tzield is administered by intravenous infusion once daily for 14 consecutive days.
The specialty pharmacy, Hy-Vee subsidiary, has 19 locations with ambulatory and home infusion capabilities.
“Living with or caring for a child with type 1 diabetes requires constant daily management,” Kristin Williams, president of Amber Specialty Pharmacy, said in a press release. “We understand how important it is for at-risk individuals to have access to medication and reliable support in order to delay disease progression.
Related: FDA Approves First Drug that Delays Diabetes
The FDA approved Tzield last week. It will be available by the end of the year at a wholesale acquisition cost of $13,850 per vial for 14-day treatment course list price of $193,900, company executives said in a call with investors.
In October 2022 the company announced a co-promotion agreement for the U.S. launch of Tzield with Sanofi.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
